Efficacy and Safety of Aflibercept 8 mg in PHOTON Trial in DMO

Opinion
Video

Dr. Marion Munk examines the Phase 2/3 clinical trial of high-dose aflibercept (8 mg) in diabetic macular oedema, presenting key outcomes and clinical implications of the data.

Newsletter

Keep your retina practice on the forefront—subscribe for expert analysis and emerging trends in retinal disease management.

Subscribe Now!
Recent Videos
Ursula Schmidt-Erfurth, MD, Professor of Ophthalmology at the Medical University of Vienna, Austria, discusses her keynote EURETINA Lecture, artificial intelligence and age-related macular degeneration.
At ARVO 2025, Christine Kay, MD, shares interim results from the PRISM trial population extension cohort
Related Content
Optain Health secures $26 million Series A funding

Optain Health secures $26 million Series A funding

Kassi Filkins
September 16th 2025
Article
New study examines soft drusen regression without atrophy and drusen ooze

New study examines soft drusen regression without atrophy and drusen ooze

Lynda Charters
September 16th 2025
Article
University of Houston researchers receive $3.6 million to examine retinal diseases

University of Houston researchers receive $3.6 million to examine retinal diseases

Jordana Joy
September 16th 2025
Article
Study links AMD to higher cardiovascular disease mortality in high-risk patients

Study links AMD to higher cardiovascular disease mortality in high-risk patients

Lynda Charters
September 16th 2025
Article
Alcon completes acquisition of LumiThera

Alcon completes acquisition of LumiThera

Martin David Harp
September 16th 2025
Article
Treating ophthalmic artery stenosis in geographic atrophy with angioplasty

Treating ophthalmic artery stenosis in geographic atrophy with angioplasty

Lynda Charters
September 16th 2025
Article
© 2025 MJH Life Sciences

All rights reserved.